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Background and aim: Procedural failure and untoward clinical outcomes after surgery remain problematic in
critical limb ischemia (CLI) patients. This study tested a clopidogrel-cilostazol combination treatment compared with
either treatment alone in attenuating CLI and improving CLI-region blood flow in rats.
Methods: Male Sprague–Dawley rats (n = 40) were equally divided into five groups: control, CLI induction only, CL
I + cilostazol (12.0 mg/day/kg), CLI + clopidogrel (8.0 mg/kg/day) and CLI + combined cilostazol-clopidogrel. After
treatment for 21 days, Laser Doppler imaging was performed.
Results: On day 21, the untreated CLI group had the lowest ratio of ischemic/normal blood flow (p < 0.001).
Inflammation measured by VCAM-1 protein expression; oxidative stress; PAI-1, MMP-9 and TNF-α mRNA expressions;
and immunofluorescence staining (IF) of CD68+ cells was lower with combined treatment than with the other
treatments, and lower in the two single-treatment groups than the untreated CLI group (all p < 0.01). Anti-
inflammatory mRNA expression of interleukin-10, and eNOS showed a reverse pattern among these groups.
Apoptosis measured by Bax, caspase-3 and PARP; and muscle damage measured by cytosolic cytochrome-C, and
serum and muscle micro-RNA-206 were all lowest with combination treatment, and the two single-treatment
groups showed lower values than the untreated group (all p < 0.001). Angiogenesis measured by eNOS, IF staining
of CD31+ and vWF+ cells; and number of vessels in CLI region were highest with combination treatment and
higher in the single-treatment groups than the untreated group (all p < 0.001).
Conclusion: Combined cilostazol-clopidogrel therapy is superior to either agent alone in improving ischemia in
rodent CLI.
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Some of the most important risk factors for atheroscler-
osis are hypercholesterolemia, hypertension, and diabetes
mellitus. Peripheral arterial disease (PAD) is character-
ized by atherosclerotic occlusion of the lower extremities
and is a common manifestation of systemic atheroscler-
osis [1]. Patients with PAD have approximately the same
relative risk of death from cardiovascular causes as those* Correspondence: han.gung@msa.hinet.net
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reproduction in any medium, provided the orwith a history of coronary or cerebrovascular disease [2],
and patients with PAD may develop critical limb ische-
mia (CLI) at later stages of the disease [3,4].
Treatment of CLI remains a formidable challenge to
the clinician. Without appropriate treatment, the 1-year
mortality rate can be as high as 25% [5]. Bypass surgical
intervention is one of the most popular and standard
methods with the highest success rate, but procedural
failure and short-term and long-term untoward clinical
outcomes in some patients remain problematic. Failure
to salvage CLI almost always leads to major limb loss
which results in a major socio-economic burden. There-
fore, development of more cost-effective treatments for
patients with CLI and those unsuitable for either surgical
or percutaneous intervention is urgently needed.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tor, is currently used in acute arterial occlusive syn-
drome for inhibiting platelet activity and thrombus
formation [6-9]. Additionally, cilostazol, a phospho-
diesterase III inhibitor approved by the US Food and
Drug Administration (FDA) for treatment of intermit-
tent claudication, has been shown to have pleiotropic
effects, including reducing smooth muscle proliferation,
limiting intimal hyperplasia after endothelial injury, low-
ering restenotic rate of endovascular intervention, and
inhibiting platelet activation and thrombus formation, as
well as reducing inflammation [10-12]. Numerous clin-
ical trials have shown that use of dual antiplatelet agents
such as combined clopidogrel and aspirin are more ef-
fective than either one used alone for reducing future
major adverse cardiac events in patients with acute cor-
onary syndrome undergoing percutaneous coronary
intervention [13-15]. However, whether combined cilos-
tazol and clopidogrel therapy can offer similar additional
benefit to improve PAD is currently unclear. This study
used a rodent CLI model to explore the effects of a com-




All animal experimental procedures were approved by
the Institute of Animal Care and Use Committee at Kao-
hsiung Chang Gung Memorial Hospital and performed
in accordance with the Guide for the Care and Use of
Laboratory Animals (NIH publication No. 85–23, Na-
tional Academy Press, Washington, DC, USA, revised
1996).
Rationale for the dosage of combined cilostazol and
clopidogrel
First, the safety and efficacy of different combinations of
cilostazol and clopidogrel were compared. Six animals
were used. They were assigned to receive low [cilostazol
(8.0 mg/kg/day) and clopidogrel (4.0 mg/kg/day)], mod-
erate [cilostazol (12.0 mg/kg/day) and clopidogrel
(8.0 mg/kg/day)] or high [cilostazol (16.0 mg/kg/day)
and clopidogrel (12.0 mg/kg/day)] dose regimens of this
combined therapy. The high-dose regimen of this com-
bined therapy easily induced wound swelling and bleed-
ing after the CLI procedure. On the other hand, wound
bleeding infrequently occurred in animals that received
the moderate and low regimens of combined therapy.
The blood flow in the CLI was markedly increased at
the moderate dosage in comparison with that with the
low dosage of this combined therapy. Therefore, the
moderate dosage of the combined therapy, cilostazol
(12.0 mg/kg/day) and clopidogrel (8.0 mg/kg/day), was
used in subsequent experiments.Treatments
Male Sprague–Dawley rats (n = 40) were equally divided
into five groups: group 1 (control), group 2 (CLI only),
group 3 [CLI + cilostazol (12.0 mg/day/kg)], group 4
[CLI + clopidogrel (8.0 mg/kg/day)], and group 5 (com-
bined cilostazol-clopidogrel) after CLI induction. All
treatments were initiated just after the CLI procedure
and continued for 21 days. The rats were sacrificed on
day 21 after the Laser Doppler was performed.
Flow cytometric quantification of endothelial progenitor
cells
For blood sampling at different time points (at 18 h and
on day 21 after induction of CLI), the tail venous route
was adopted for blood sampling using 27# needle. After
treatment with red blood cell-lysing buffer for the blood
sample, the cells remained were labeled with appropriate
antibodies. Flow cytometric analysis for identification of
cell surface markers was performed based on our recent
reports [16]. Briefly, the cells were immunostained for
30 minutes with monoclonal antibodies against primary
antibodies, including CD 31 (serotec), C-kit-FITC (BD
biosciences), Sca-1-PE (R&D), CXCR4 (Abcam), and
CD34-PE (BD biosciences). Secondary detection was
performed using appropriate Alexa Fluor 488 (Molecular
Probes, Eugene, OR). Isotype-identical antibodies (IgG)
served as controls. Flow cytometric analyses were per-
formed by utilizing a fluorescence-activated cell sorter
(Beckman Coulter FC500 flow cytometer). Measure-
ment of Blood Flow with Laser Doppler (Figure 1)
Rats were anesthetized by intraperitoneal injections of
isoflurane (2.0%) prior to CLI induction and at days 2
and 21 after CLI induction prior to be sacrificed. The
rats were placed in a supine position on a warming pad
at 37 °C and the blood flow were detected in both in-
guinal areas by a Laser Doppler scanner (moorLDLS,
Moor, Co. UK). The ratio of flow in left (ischemic) leg
and right (normal) leg was computed. The rats were
sacrificed and the quadriceps muscle was collected for
individual study.
Western blot analyses
Equal amounts (50 μg) of protein extracts were loaded
and separated by SDS-PAGE using acrylamide gradients.
After electrophoresis, the separated proteins were trans-
ferred electrophoretically to a polyvinylidene difluoride
(PVDF) membrane (Amersham Biosciences). Nonspecific
sites were blocked by incubation of the membrane in
blocking buffer [5% nonfat dry milk in T-TBS (TBS con-
taining 0.05% Tween 20) overnight. The membranes
were incubated with the indicated primary antibodies
[vascular cell adhesion molecule (VCAM)-1 (1:100,
Abcam), cytochrome c (Cyt c) (1: 2000, BD), Bax (1:
1000, Abcam), caspase 3 (1:1000, Cell Signaling), poly
Figure 1 Flow cytometric quantifications of circulating numbers of endothelial progenitor cells (EPCs) at 18 h and day 21 after critical
limb ischemia (CLI) procedure (n = 8). A & B) circulating number of C-kit/CD31+ cells at 18 h and day 21. By day 21,* vs. other groups with
different symbols (i.e.,* vs. † vs. {), p < 0.001. C & D) circulating number of Sca-1/CD31+ cells at 18 h and day 21. At 18 h,* vs. other groups with
different symbols, p < 0.008. At day 21,* vs. other groups with different symbols, p < 0.01. E & F) circulating number of CXCR4+ cells at 18 h and
day 21. At 18 h,* vs. other groups with different symbols, p < 0.001. G & H) circulating number of CD31+ cells. By day 21,* vs. other groups with
different symbols, p < 0.001. Statistical analysis in each group by ANOVA followed by Bonferroni multiple comparison post hoc test. CLI = critical
limb ischemia; Cil = cilostazol; Clo = clopidogrel.
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endothelial nitric oxide synthase (eNOS) (1: 1000,
Abcam), Actin (1: 10000, Chemicon )] for 1 hour at room
temperature. Horseradish peroxidase -conjugated anti-
rabbit immunoglobulin IgG (1: 2000, Cell Signaling) was
used as a second antibody for one hour at room
temperature. The washing procedure was repeated eight
times within one hour, and immunoreactive bands were
visualized by enhanced chemiluminescence (ECL; Amer-
sham Biosciences) and exposure to Biomax L film(Kodak). For purposes of quantification, ECL signals
were digitized using Labwork software (UVP).
Oxidative stress reaction of LV myocardium
The Oxyblot Oxidized Protein Detection Kit was pur-
chased from Chemicon (S7150). DNPH derivatization
was carried out on 6 μg of protein for 15 minutes accord-
ing to manufacturer’s instructions. One-dimensional
electrophoresis was carried out on 12% SDS/polyacryl-
amide gel after DNPH derivatization. Proteins were
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incubated in the primary antibody solution (anti-DNP 1:
150) for 2 hrs, followed by incubation with second anti-
body solution (1:300) for 1 hr at room temperature. The
washing procedure was repeated eight times within
40 minutes. Immunoreactive bands were visualized by
enhanced chemiluminescence (ECL; Amersham Bios-
ciences) which was then exposed to Biomax L film
(Kodak). For quantification, ECL signals were digitized
using Labwork software (UVP). For oxyblot protein ana-
lysis, a standard control was loaded on each gel.
Isolation of mitochondria from quadriceps
The skeletal muscle from ischemic region was excised
and washed with buffer A (100 mM Tris–HCl, 70 mM
sucrose, 10 mM EDTA and 210 mM mannitol, pH 7.4).
The samples were first minced finely in cold buffer A
and then incubated for 10 minutes at 4°C. All samples
were then homogenized in an additional 3 mL of buffer
A using a motor-driven grinder. The homogenate was
centrifuged twice at 700 g for 10 minutes at 4°C. The
supernatant was again centrifuged at 8,500 g for 15 min-
utes, and the pellets were then washed with buffer B
(10 mM Tris–HCl, 70 mM sucrose, 1 mM EDTA, and
230 mM mannitol, pH 7.4). The mitochondria-rich pel-
lets were finally collected and stored at −70°C for the in-
dividual study.
Real-time quantitative PCR analysis
Real-time reverse transcription polymerase chain reac-
tion (RT-qPCR) was conducted using LighCycler Taq-
Man Master (Roche, Germany) in a single capillary tube
according to the manufacturer’s guidelines for individual
component concentrations. Forward and reverse primers
were each designed in a different exon of the target gene
sequence, eliminating the possibility for amplifying gen-
omic DNA.
Total RNA was extracted using spin column-based
RNA extraction kit (RNeasy Fibrous Tissue Mini Kit,
Qiagen) according to protocols provided by manufac-
turer. Reverse transcriptions were performed with the
Transcriptor First Strand cDNA Synthesis Kit (Roche).
Briefly, 1 μg of total RNA was mixed with 50 pmole
oligo dT and then incubated at 65°C for 10 minutes.
After incubation on ice for 5 minutes, 4 μL of 5x reverse
transcriptase reaction buffer, 0.5 μL of RNase inhibitor
(40 U/μl), 2 μL of dNTP (10 mM for each), and 0.5 μL
of reverse transcriptase (20 U/μL) were added into tubes
containing hybridized RNA-oligo dT mixtures. RT reac-
tions were carried at 55°C for 30 minutes. PCRs were
performed on a Light Cycler (Roche Molecular Bio-
chemicals). Each reaction was carried out with 1 μL of
cDNA, 5 μL of 2x reaction mixtures (Maxima Probe
qPCR Master Mix), 0.15 μL or each primer (20 μM), 0.2μL of probe, and 3.5 μL of sterile distilled water. Reac-
tions were performed by incubating in 95°C for 10 min-
utes, following with 45 cycles of 95°C for 10 sec, 60°C
for 30 sec, and 72°C for 1 sec. Analysis of melting curves
and determination of threshold cycle (Ct) were per-
formed by the Light Cycler instrument’s software pro-
vided by Roche.Immunofluorescent (IF) and immunohistochemical (IHC)
studies
For IF staining, cryo-sections were fixed with cold acet-
one for 3 min and then incubated with primary antibody
specifically against CD31 (1:200, Serotec) at 4°C over-
night. After wash with PBS, sections were incubated
Alexa Fluor 594-conjugated goat anti-mouse IgG sec-
ondary antibodies for 30 min at room temperature and
followed by counter-staining with DAPI. Fluorescent sig-
nals were observed with fluorescent-equipped micro-
scope (IX-41, Olympus).
For IHC staining, rehydrated paraffin sections were
firstly treated with 3% H2O2 for 30 min and incubated
with Immuno-Block reagent (BioSB) for 30 min at room
temperature. Sections were then incubated with incu-
bated with primary antibodies specifically against von
Willebrand factor (vWF) (1:200, Millipore), at 4°C over-
night. Irrelevant antibodies [(p53, 1: 500 (Abcam) and
mouse control IgG (Abcam)] were used as controls in
the current study. After washing with PBS thrice, the
sections were incubated PolyDetector HRP Label
(BioSB) for 30 min and washed with PBS thrice again.
Finally, section were covered with DAB substrate-
chromogen solution (BioSB) for 5 min and followed by
counter-staining with hematoxylin. Three sections of
muscle specimens were analyzed in each rat.
For quantification, three randomly selected HPFs
(x100 for IHC stain and 400x for IF stain respectively)
were analyzed in each section. The mean number per
HPF for each animal was then determined by summa-
tion of all numbers divided by 9.Vessel density in CLI region
IHC staining for determining the number of vessels was
performed with primary antibody against α-SMA (1:400)
with incubation at room temperature for one hour, fol-
lowed by washing with PBS thrice. The anti-mouse-HRP
conjugated secondary antibody was then added for
10 minutes, followed by washing with PBS thrice. Three
ischemia sections were analyzed in each animal. For
quantification, three randomly selected high-power fields
(HPFs) (100x) were analyzed in each section. The mean
number per HPF for each animal was then determined
by summation of all numbers divided by 9.
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Quantitative data are expressed as means ± SD. Statis-
tical analysis was adequately performed by ANOVA fol-
lowed by Bonferroni multiple-comparison post hoc test.
Statistical analysis was performed using SAS statistical
software for Windows version 8.2 (SAS institute, Cary,
NC). A probability value <0.05 was considered statisti-
cally significant.
Results
Combined cilostazol and clopidogrel treatment increases
numbers of circulating EPCs in critical limb ischemia
Flow cytometric analysis was performed to investigate the
effect of cilostazol and clopidogrel treatment on circulat-
ing endothelial progenitor cells (EPCs) at 18 h and on day
21 after the CLI procedure (Figure 1). Double staining for
C-kit/CD31+ (Figure 1-A & B) and Sca-1/CD31+
(Figure 1-C to 1-D); and single staining for CXCR4+
(Figure 1-E & F) and CD34+ (Figure 1-G & H) were used.
At 18 h after the CLI procedure, the number of circu-
lating C-kit/CD31+ cells (Figure 1-A) did not differ
among the five groups. On day 21 after the procedure,
the number of circulating C-kit/CD31+ cells (Figure 1-B)
showed no significant difference between the untreated
control group and the CLI only group, or between the
control group and the two groups that received treat-
ment with either cilostazol and clopidogrel; but, the
number of circulating C-kit/CD31+ (Figure 1-B) cells
was significantly higher in all the treatment groups
(groups 3–5) than in the CLI group that received no
treatment (group 2). Among the treatment groups the
number of circulating C-kit/CD31+ cells (Figure 1-B)
was notably higher in the group that received the com-
bination therapy (group 5).
At 18 h after the CLI procedure, the number of circu-
lating number of Sca-1/CD31+ cells (Figure 1-C) showed
no significant difference between the control group, the
CLI only group and the two groups receiving either
cilostazol and clopidogrel treatment, or among groups 3
to 5, but was significantly higher in the group receiving
the combination treatment (group 5) than in the control
group or the CLI group (group 1) with no treatment
(group 2). By day 21 after the procedure, the circulating
level of these biomarkers revealed no difference among
groups 1 to 4 or among groups 3 to 5 (Figure 1-D).
However, this circulating biomarker level was still much
higher in group 5 than in groups 1 and 2.
At 18 hours after the CLI procedure, the number of
circulating CXCR4+ cells (Figure 1-E) displayed no dif-
ference between groups 1, 2 and 3, or between groups 4
and 5. However, there were significantly more circulating
CXCR4+ cells in groups 4 and 5 than in groups 1, 2 and
3. By day 21 after the procedure, there was no significant
difference among the five groups (Figure 1-F).At 18 hours after the CLI procedure, there was no
difference in the number of circulating CD34+ cells
(Figure 1-G) among the five groups. By day 21 after
the procedure (Figure 1-H), there was no difference in
the number of circulating CD34+ cells among groups
1 to 4, but there was a significantly higher number in
group 5 than in groups 1 to 4. Together these results
suggest that combined cilostazol and clopidogrel treat-
ment increases the number of circulating EPCs.
Combined cilostazol and clopidogrel treatment decreases
inflammation and oxidation in critical limb ischemia
The mRNA expressions of tumor necrotic factor (TNF)-
α, matrix metalloproteinase (MMP)-9 and plasminogen
activator inhibitor (PAI)-1, three indices of inflamma-
tion, were much higher in the untreated CLI group
(group 2) than in the control (group 1), and the experi-
mental groups (groups 3, 4 and 5); higher in groups 3
and 4 than in groups 1 and 5, but showed no difference
between groups 3 and 4 (Figure 2). Conversely, the
mRNA expressions of interleukin (IL)-10 and endothelial
nitric oxide synthase (eNOS), two indices of anti-inflam-
mation, were significantly lower in groups 1 and 2 than
in groups 3 to 5 and significantly lower in groups 3 and
4 than in group 5, but it revealed no difference between
groups 3 and 4. Additionally, eNOS mRNA expression
was significantly lower, whereas the IL-10 mRNA ex-
pression was higher in group 2 than in group 1.
Oxidative stress (Figure 3-A & B), an indicator of in-
flammation, was increased in the non-treated CLI group
(group 2) in comparison with the other groups,
increased in groups 3 and 4 in comparison with group 5,
significantly increased in group 5 in comparison with
group 1, but there was no difference between groups 3
and 4. Additionally, the protein expression of vascular
adhesion molecule (VCMA)-1 (Figure 3-C), another in-
dicator of inflammation, was increased in the untreated
CLI group (group 2) in comparison with the other
groups, increased in groups 3 and 4 in comparison with
group 5, but revealed no difference among groups 1, 3
and 4, or between groups 1 and 5. Furthermore, the
number of CD68+ cells, an indicator of inflammatory
cell infiltration, as shown by IF staining, showed a simi-
lar pattern as oxidative stress among the five groups
(Figure 3-D to I).
Combined cilostazol and clopidogrel treatment reduces
skeletal muscle damage in critical limb ischemia
The serum and ischemic muscle microRNA-206 (Figure 4-
A and B), an index of skeletal muscle damage, was signifi-
cantly higher in non-treated CLI group (group 2) than in
the other groups, significantly higher in groups 3 and 4
than in groups 1 and 5, significantly higher in group 5
than in group 1, but it showed no difference between
Figure 2 The mRNA expressions of inflammatory and anti-inflammatory biomarkers in ischemic quadriceps by day 21 after CLI
procedure (n = 8). A, B and C) indicating mRNA expressions of tumor necrotic factor (TNF-α), matrix metalloproteinase (MMP-9), and
plasminogen activator inhibitor (PAI)-1, respectively.* vs. other groups with different symbols, p < 0.0004. D & E) showing mRNA expressions of
interleukin (IL)-10 and endothelial nitric oxide (eNOS), respectively.* vs. other groups with different symbols, p < 0.009. Statistical analysis in each
group by ANOVA followed by Bonferroni multiple comparison post hoc test. CLI = critical limb ischemia; Cil = cilostazol; Clo = clopidogrel.
Sheu et al. Journal of Translational Medicine 2012, 10:164 Page 6 of 14
http://www.translational-medicine.com/content/10/1/164groups 3 and 4. Conversely, the mRNA expression of per-
oxisome proliferator-activated receptor-γ coactivator-1α
(PGC-1α) (Figure 4-C), an energy transcriptional coactiva-
tor, a major upstream regulator of mitochondrial metabol-
ism and biogenesis, revealed an altered pattern of
microRNA-206 among the five groups.
The protein expression of cytochrome C in mitochon-
dria (Figure 4-D), an indicator of energy supply and stor-
age in mitochondria, was significantly lower in the
untreated CLI group (group 2) than in other groups, sig-
nificantly lower in groups 3 to 5 than in the controls
(group 1), but similar among groups 3, 4 and 5. In con-
trast, the protein expression of cytochrome C in the
cytosol (Figure 4-E), an indicator of mitochondrial dam-
age, was significantly higher in the untreated CLI group
(group 2) than in other groups, significantly higher in
groups 3 and 4 than in groups 1 and 5, and significantly
higher in group 5 than in group 1, but it exhibited no
difference between groups 3 and 4.
Combined cilostazol and clopidogrel treatment reduces
apoptosis in critical limb ischemia
The mRNA expressions of caspase-3 (Figure 5-A) and
Bax (Figure 5-B), two indices of apoptosis, were highestin the untreated CLI group (group 2), higher in groups 3
and 4 than in groups 1 and 5, and higher in group 5
than in group 1, but there was no difference between
groups 3 and 4. Additionally, the mitochondrial protein
expression of Bax (Figure 5-C) displayed a similar pattern
as the mRNA expression of Bax among the five groups.
In contrast, mRNA expression of Bcl-2 (Figure 5-D), an
index of anti-apoptosis, displayed an altered characters
among the five groups.
Poly(ADP-ribose) polymerase (PARP) cleavage (i.e.,
active form), an indicator of apoptosis, was signifi-
cantly higher in group 2 than in the other groups,
significantly higher in groups 3 and 4 than in groups
1 and 5, notably higher in group 5 than in group 1,
but it showed no difference between groups 3 and 4
(Figure 6-A).
Cleaved caspase 3 (i.e., active form) was signifi-
cantly higher in groups 2 than in other groups, sig-
nificantly higher in groups 3 and 4 than in groups 1 and
5, higher in group 5 than in group 1, but it showed no
difference between groups 3 and 4 (Figure 6-B). These
results suggest that less apoptosis occurs in critical limb
ischemia after combined cilostazol and clopidogrel
treatment.
Figure 3 Western blot result of oxidative stress and protein and cellular inflammatory biomarkers for ischemic quadriceps by day 21
following CLI procedure (n = 8). A) oxidative index (protein carbonyls) among five groups of animals (a = control, b = CLI only,
c = CLI + cilostazol, d = CLI + clopidogrel, e = CLI + combined therapy). B)* vs. other groups with different symbols, p < 0.005. (Note: Right lane and
left lane shown on upper panel represent control oxidized molecular protein standard and protein molecular weight marker, respectively).
DNP= 1-3 dinitrophenylhydrazone. C) protein expression of intercellular adhesion molecule (ICAM)-1. D to H) immunofluorescent (IF) microscopic
(400x) findings of CD 68+ cells (white arrows). I)* vs. other groups with different symbols, p < 0.0001. Nuclei (blue color) stained with 4’,6-
diamidino-2-phenylindole (DAPI) as counter staining. The scale bars in right lower corner represent 20 μm. Statistical analysis in each group by
ANOVA followed by Bonferroni multiple comparison post hoc test. CLI = critical limb ischemia; Cil = cilostazol; Clo = clopidogrel.
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angiogenesis in the CLI region
The protein expression of endothelial nitric oxide syn-
thase (eNOS) (Figure 6-C), an index of angiogenesis and
an anti-inflammatory factor, was lower in the untreated
CLI group (group 2) than in the other groups, lower in
the two groups that received a single treatment than in
the controls (group 1) and the combined treatment
group (group 5), significantly lower in the combined
treatment group (group 5) than in the controls (group
1), but it did not differ between the two single treatment
groups. Additionally, IF staining showed that the num-
bers of CD31+ and vWF+ cells (Figure 7), two indices of
angiogenic cells, were significantly lower in the un-
treated CLI group (group 2) than in the other groups,
significantly lower in groups 3 and 4 than in groups 1
and 5, and significantly lower in group 5 than in group
1, but it showed no difference between groups 3 and 4.Furthermore, IHC staining showed that the small num-
ber of vessels (<15 μm) in the CLI region exhibited an
identical pattern of IF staining among the five groups
(Figure 8).
Blood flow in the CLI region is improved with combined
cilostazol and clopidogrel treatment
The ratio of ischemic/normal blood flow (INBF) did not
show any difference among the five groups prior to the
CLI procedure. But by day 21 after CLI induction, the
INBF ration was significantly reduced in the CLI group
receiving no treatment in comparison with the other
groups, and was significantly lower in the two groups re-
ceiving a single treatment in comparison with the con-
trol group (groups 1) and the group receiving cilostazol
and clopidogrel combination treatment (group 5), and
significantly lower in combination treatment group than
in the normal controls, but it displayed no difference
Figure 4 mRNA and protein expressions of skeletal muscle damage markers in ischemic quadriceps by day 21 following CLI procedure
(n = 8). A and B) showing serum and ischemic muscle microRNA-206 levels, respectively. For (A) and (B),* vs. other groups with different symbols,
p < 0.0001. C) mRNA expression of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α).* vs. other groups with different symbols,
p < 0.0001. D) mitochondrial cytochrome C (Cyt C) protein expression.* vs. other groups with different symbols, p < 0.008. E) Cytosolic cytochrome
C protein expression.* vs. other groups with different symbols, p < 0.004. Statistical analysis in each group by ANOVA followed by Bonferroni
multiple comparison post hoc test. CLI = critical limb ischemia; Cil = cilostazol; Clo = clopidogrel.
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(groups 3 and 4) (Figure 9).
Discussion
This study investigated the therapeutic effect of com-
bined cilostazol and clopidogrel treatment on a murine
model of CLI. Several observations were made: First,
CLI without treatment markedly enhanced inflamma-
tion, oxidative stress, cellular apoptosis and tissue fibro-
sis in mice. Second, serum microRNA-206 level was a
simple and useful biomarker for determining the skeletal
muscle ischemia/damage. Third, cilostazol or clopidogrel
therapy used alone showed similar effects on inflamma-
tion, oxidative stress, cellular apoptosis, ischemia-related
muscle damage and tissue fibrosis, but combination
treatment of these two drugs had a more pronounced
suppressive effect than either agent used alone. Cilosta-
zol and clopidogrel combination treatment was superior
to either drug alone for enriching angiogenic factors andblood vessel density and improving blood flow in the is-
chemic area.
Inflammation and oxidative stress are two key factors
thought to be associated with endothelial dysfunction,
and consequent atherosclerosis, plaque rupture and
acute arterial occlusive syndrome [17-20]. They are also
increased [21-25] and play crucial roles in continued
progressive damage to organs after acute ischemic attack
[22,25]. One important finding of the current study was
that compared to the normal control, inflammation and
oxidative-stress were substantially increased in rats after
CLI, findings which support previous studies [21-25].
Inflammation and oxidative-stress were significantly
suppressed after cilostazol or clopidogrel therapy. A
previous study showed that cilostazol therapy markedly
suppressed the expressions of the TNF-α and MMP-9,
two indicators of inflammation, in lung parenchyma of
pulmonary arterial hypertension rats [26]. Additionally,
our previous studies and those of others have shown
Figure 5 Protein and mRNA expressions of apoptotic biomarkers in ischemic quadriceps by day 21 following CLI procedure (n = 8). A
and B) showing mRNA expression of caspase 3 and Bax, respectively. for (A) and (B), * vs. other groups with different symbols, p < 0.0001. C)
mitochondrial protein expression of Bax. * vs. other groups with different symbols, p < 0.008. D) mRNA expression of Bcl-2. * vs. other groups with
different symbols, p < 0.0001. Statistical analysis in each group by ANOVA followed by Bonferroni multiple comparison post hoc test. CLI = critical
limb ischemia; Cil = cilostazol; Clo = clopidogrel.
Figure 6 Western blot results of apoptotic and angiogenic factors in ischemic quadriceps by day 21 following CLI procedure (n = 8). A)
protein expression of cleaved (C) poly(ADP-ribose) polymerase (PARP).* vs. other groups with different symbols, p < 0.006. B) protein expression of
cleaved casapse 3 (C-Csp-3).* vs. other groups with different symbols, p < 0.004. C) protein expression of endothelial nitric oxide synthase (eNOS).*
vs. other groups with different symbols, p < 0.002. Statistical analysis in each group by ANOVA followed by Bonferroni multiple comparison post
hoc test. CLI = critical limb ischemia; Cil = cilostazol; Clo = clopidogrel.
Sheu et al. Journal of Translational Medicine 2012, 10:164 Page 9 of 14
http://www.translational-medicine.com/content/10/1/164
Figure 7 Quantification of immunofluorescent (IF) (400x) and immunohistochemical (IHC) (200x) staining for ischemic quadriceps by
day 21 following CLI procedure (n = 8). A to E) showing the IF stain of CD31+ cells (white arrows) in five groups (A = control, B = CLI only,
C = CLI + cilostazol, D = CLI + clopidogrel, E = CLI + combined therapy). F)* vs. other groups with different symbols, p < 0.0001. Nuclei (blue color)
stained with 4’,6-diamidino-2-phenylindole (DAPI) as counter staining. The scale bars in right lower corner represent 20 μm. G to K) indicating the
results of IHC stain of von Willebrand factor (vWF) + cells (red arrows) in five groups (G = control, H = CLI only, I = CLI + cilostazol,
J = CLI + clopidogrel, K = CLI + combined therapy). L)* vs. other groups with different symbols, p < 0.0001. The scale bars in right lower corner
represent 50 μm. CLI = critical limb ischemia; Cil = cilostazol; Clo = clopidogrel.
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http://www.translational-medicine.com/content/10/1/164that clopidogrel therapy significantly attenuated circulat-
ing levels of soluble CD40 ligand and high-sensitivity
C-reactive protein (hs-CRP), two indicators of inflam-
mation, and reduced oxidative stress [27-29]. How-
ever, the present study showed that combined cilostazol
and clopidogrel therapy more markedly inhibited theinflammatory and oxidative-stress responses, thus,
extending the findings of previous studies [26-29].
The association between ischemia and inflammation,
and incremental cellular apoptosis and death is well
known [24,25,29,30]. In the current study, compared
with the normal control, both mRNA and protein levels
Figure 8 Immunohistochemical (IHC) (200X) staining of alpha-smooth muscle actin for quantification of small vessel (≤ 15.0 μm) in
ischemic quadriceps at day 21 after CLI induction (n = 8). A to E) indicating IHC stain of number of small vessels (≤ 15 μm) (red arrows) in
five groups (A = control, B = CLI only, C = CLI + cilostazol, D = CLI + clopidogrel, E = CLI + combined therapy). F) * vs. other groups with different
symbols, p < 0.001. Statistical analysis by ANOVA followed by Bonferroni multiple comparison post hoc test. Scale bars in right lower corner
represent 50 μm. HPF= high-power field (200x). CLI = critical limb ischemia; Cil = cilostazol; Clo = clopidogrel.
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http://www.translational-medicine.com/content/10/1/164of apoptosis biomarkers were substantially increased
in CLI animals; however, these apoptotic parameters
were remarkably reduced in CLI animals after receiv-
ing cilostazol or clopidogrel therapy. Conversely, theFigure 9 Laser Doppler scanning of hind limb blood flow on day 21 a
limbs), (B) (isolated left hind limb scanning) and (C) (isolated right hind lim
among five groups prior to the procedure. F to J) ratio of ischemic/normal
H=CLI + cilostazol, I = CLI + clopidogrel, J = CLI + combined therapy) by day
p< 0.001. Statistical analysis by ANOVA followed by Bonferroni multiple com
Clo= clopidogrel.anti-apoptotic biomarkers which were reduced in CLI
animals were markedly upregulated in those CLI ani-
mals with cilostazol or clopidogrel therapy. Previous
studies have also revealed the effect of cilostazol andfter CLI induction (n= 8). (A) (simultaneous scanning of both hind
b scanning) in normal rats. D) Normal blood flow in both hind limbs
blood flow (INBF) among five groups (F = control, G = CLI only,
21 after CLI procedure. E)* vs. other groups with different symbols,
parison post hoc test. CLI = critical limb ischemia; Cil = cilostazol;
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http://www.translational-medicine.com/content/10/1/164clopidogrel therapy significantly inhibited the cellular
apoptosis in ischemic tissues/organs [26,29]. Combined
therapy with these two agents further ameliorated apop-
tosis and enhanced the anti-apoptotic effect to a much
greater extent than in either agent alone after CLI. Our
findings further show that serum and ischemic muscle
of levels of microRNA-206, an index of skeletal muscle
damage, were further reduced; and mitochondrial cyto-
chrome C and PGC-1α were more significantly pre-
served with combined cilostazol or clopidogrel therapy
in comparison with either treatment used alone.
One particularly distinctive finding in the present
study was that the circulating level of EPCs, the pro-
tein expression of eNOS, the number of small blood
vessels and the numbers of CD31+ and vWF+ cells
(i.e., new endothelial cells) in CLI region were promin-
ently increased in CLI animals with cilostazol or clopi-
dogrel therapy. Combined treatment with cilostazol and
clopidogrel was superior to either treatment used alone
for enhancing exhibition of these angiogenic factors
both in circulation and in the ischemic region. These
findings may explain why the Laser Doppler results of
blood flow in CLI area was significantly improved in
animals that underwent monotherapy and further
improved in animals receiving combined therapy in
comparison to those animals without treatment. We
have previously demonstrated that cilostazol therapy
enhanced the eNOS mRNA expressions in both lung
and right ventricle in a rat model of pulmonary arterialFigure 10 Proposed mechanisms underlying the effects of different t
present study. EPC= endothelial progenitor cell; eNOS= endothelial nitric
proliferator-activated receptor-γ coactivator-1α; Cyt C = cytochrome C; PARP
PAI-1 = plasminogen activator inhibitor 1; TNF-α= tumor necrotic factor-α; I
miRNA=microRNA; INBF = ratio of ischemic to normal blood flow.hypertension [26]. Additionally, cilostazol has been
previously shown to enrich vasculogenesis through en-
hancing EPC mobilization from bone marrow to circu-
lation and promoting the production of angiogenic
factors and chemokines [i.e., eNOS, CXCR4, vascular
endothelial growth factor (VEGF) and stromal cell
derived factor (SDF)-1α] [30] for recruiting and mobil-
izing new EPCs/endothelial cells to ischemic region
[31,32]. The findings from these studies [26,31,32] have
been reinforced by the results from another previous
study [33] which has demonstrated that vardenafil, a
PDE-5 inhibitor, enhanced ischemia-induced angiogen-
esis with mobilization of EPCs through a protein kin-
ase G–dependent hypoxia-inducible factor (HIF)-1α/
VEGF. Furthermore, it has previously been shown that
clopidogrel therapy significantly increased the number
of EPCs [34,35]. Moreover, clopidogrel treatment in
patients with coronary artery disease not only inhibits
platelet activation but also improves endothelial func-
tion and nitric oxide bioavailability [36]. Besides, study
[36] has further displayed clopidogrel improved adeny-
lyl cyclase-mediated signaling including increased Akt-
and eNOS-phosphorylation contributing to improved
NO-mediated vasorelaxation [36] and EPC mobilization
[34,35]. Accordingly, in addition to reinforcing these pre-
vious findings [26,31-36], our results raise the possibility
of using a combined regimen for CLI patients who are
not candidates for bypass surgery and catheter-based
intervention.reatment on CLI in a rat model based on the findings of the
oxide synthase; vWF = von Willebrand factor; PGC-1α=peroxisome
=poly(ADP-ribose) polymerase; MMP-9 =matrix metalloproteinase;
L-10 = interleukin-10; VCAM-1 = vascular cell adhesion molecule 1;
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This study has several limitations. First, this study did
not investigate the contribution of cilostazol or clopido-
grel to anti-thrombosis and anti-platelet activity. There-
fore, it is unclear whether reducing thrombosis and
platelet activity would potentially contribute to increase
in blood flow in the CLI area. Second, the underlying
mechanism responsible for the upregulation of EPCs in
circulation and the new endothelial cells in CLI region
has not been explored in the current study. A previous
study suggested that these changes could be due to
mobilization from the bone marrow, or alternatively a
decrease in the peripheral apoptotic destruction of EPCs
[34]. Third, the results of the current study did not ad-
dress whether the mechanisms of cilostazol and clopido-
grel therapy were the same or different and if the high
dosage of cilostazol or clopidogrel might work as well as
both of them in the moderate for increasing EPC num-
ber in circulation and generating eNOS and angiogenesis
in ischemia area.
In conclusion, our results demonstrated that cilostazol
and clopidogrel combined therapy has a synergic effect
on rat CLI. The proposed mechanisms are summarized
in Figure 10. This finding may expand the potential
applications of this therapeutic modulation not only for
CLI patients but also for patients with intracranial arterial
obstructive syndrome [37].
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